I wonder what the outcome would have been had the efficacy assessment been based on mba alone. Would that constitute proof and we would be progressing rapidly to commercialisation?
If they have got fda signed off on mba as the efficacy criteria, as could be assumed from their comments, surely NEU just has to repeat the same outcome and we are in business. I am pretty optimistic.
Ann: Neuren presents at Rettsyndrome.org 2016 Research Symposium-NEU.AX, page-4
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.62 |
Change
-0.240(1.15%) |
Mkt cap ! $2.635B | |||
| Open | High | Low | Value | Volume |
| $20.45 | $20.62 | $20.26 | $4.698M | 229.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 221 | $20.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.62 | 1553 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |